Nivolumab Lifts ctDNA Clearance to 66% in Resectable NSCLC, Tied to 0.29 EFS Hazard Ratio
Updated
Updated · Oncodaily · Aug 14
Nivolumab Lifts ctDNA Clearance to 66% in Resectable NSCLC, Tied to 0.29 EFS Hazard Ratio
2 articles · Updated · Oncodaily · Aug 14
Summary
Perioperative nivolumab achieved 66% preoperative ctDNA clearance versus 38% with placebo in resectable non-small cell lung cancer, according to biomarker data shared by Jarushka Naidoo.
CM77T sample counts were 98 for nivolumab and 92 for placebo, and ctDNA clearance linked with pathologic complete response was associated with better event-free survival versus no pCR, with a hazard ratio of 0.29.
KEAP1, STK11, CDKN2A and SMARCA4 biomarker findings were also tied to progression-free survival, with a reported hazard ratio of 0.48.
The data add to efforts to identify which resectable NSCLC patients derive the strongest benefit from perioperative nivolumab before surgery.